[Utility of beta-blockers in the treatment of chronic heart failure]

Related Experiment Videos

D Martín Raymondi1, A Velasco, A Cordero

  • 1Departamento de Cardiología, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Avda. Pío XII, 36, 31008 Pamplona. dmartinr@unav.es

Revista De Medicina De La Universidad De Navarra
|November 26, 2003
PubMed

Insights

Beta-blockers are recommended for patients with heart failure, a common condition in older adults. This review examines clinical trials supporting beta-blocker use and discusses treatment benefits and considerations.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Heart failure (HF) affects 2-3% of individuals over 65.
  • HF represents a significant public health challenge with substantial economic burden.
  • Treatment of HF-related complications incurs high annual costs.

Purpose:

  • To review randomized prospective trials evaluating beta-blocker efficacy in heart failure patients.
  • To analyze the clinical benefits associated with beta-blocker therapy for heart failure.
  • To discuss specific considerations for prescribing beta-blockers in this population.

Summary:

  • Analysis of randomized trials supports the use of beta-blockers for heart failure management.
  • Beta-blockers offer significant benefits in treating patients with heart failure.
  • The review includes an examination of special considerations for beta-blocker drug use.

Impact:

  • Provides evidence-based support for beta-blocker therapy in heart failure.
  • Informs clinical practice regarding the benefits and considerations of beta-blockers.
  • Contributes to understanding optimal management strategies for heart failure.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...